June 17 (Reuters) - Japan's Takeda said on

Monday its experimental drug to treat epileptic disorders failed

to meet the main goal in two late-stage studies.

The drug, soticlestat, was being tested in adult and

pediatric patients with Dravet syndrome and Lennox-Gastaut

syndrome.

These are severe forms of epilepsy characterized by

frequent, prolonged seizures, that typically becomes apparent

during infancy or early childhood.

Takeda plans to discuss with regulatory authorities to

determine next steps.